Could donor cells stop MS progression? early trial launches
NCT ID NCT07477639
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a cell therapy called TRX319 in 39 adults with progressive multiple sclerosis (MS). The goal is to see if it is safe and to find the best dose. Participants receive TRX319 infusions, sometimes after a chemotherapy drug called bendamustine, and are followed for one year with blood tests, MRI scans, and spinal taps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRX319 (a cell therapy made from donor cells) and bendamustine (a chemotherapy drug used to prepare the body)
What this could lead to
If it works, this could point toward a new treatment that slows or stops worsening disability in progressive multiple sclerosis.
What could go wrong
This is a very early, small trial (39 people) focused on safety. The therapy may not work, and side effects from the cell infusion or bendamustine could occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University, St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••